Incyte Achieves $25-Million Milestone for Jakavi Approval
Incyte Corporation announced it has earned a $25-million milestone payment from Novartis in connection with the approval of Jakavi (ruxolitinib) in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract revenue in the third quarter. Under the Incyte-Novartis Collaboration and License Agreement, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi (ruxolitinib).
“We are very pleased with the progress that Novartis is making in the global roll-out of Jakavi,” said Hervé Hoppenot, President and Chief Executive Officer of Incyte. “The recent approval of Jakavi in Japan is further evidence of that progress.”
Novartis also continues to make progress in obtaining formal pricing and reimbursement approval for a third major European country and expects this to occur in the second half of 2014. Once achieved, Incyte will earn an additional $60-million milestone payment.
Jakafi is a prescription medicine approved by the US FDA to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.
Incyte Corporation is a Wilmington, DE-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary small molecule drugs, primarily for oncology. For more information, visit www.incyte.com.
Total Page Views: 938
